Want to take quizzes and track your credits?
Opioid mortality rates continue to increase throughout the United States1; however, growth in buprenorphine hydrochloride treatment for opioid use disorder (OUD) might be limited to communities with higher income and low percentages of racial/ethnic minorities.2 Buprenorphine, a partial opioid agonist, is 1 of 3 evidence-based medications for treating OUD and can legally be prescribed in office-based settings.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: March 12, 2019.
Corresponding Author: Pooja Lagisetty, MD, MSc, NCRC B16-Floor 2, 2800 Plymouth Rd, Ann Arbor, MI 48109 (email@example.com).
Published Online: May 8, 2019. doi:10.1001/jamapsychiatry.2019.0876
Author Contributions: Dr Lagisetty and Mr Ross had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Lagisetty.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Lagisetty, Ross, Maust.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Ross.
Administrative, technical, or material support: Lagisetty, Clay.
Supervision: Lagisetty, Maust.
Other - mentoring: Bohnert.
Conflict of Interest Disclosures: None reported.
You currently have no searches saved.